Selzentry
Generic name: Maraviroc
Drug class:
Chemokine receptor antagonist
Usage of Selzentry
Selzentry is an antiviral medicine that prevents certain viral cells from multiplying in your body.
Selzentry prevents human immunodeficiency virus (HIV) from multiplying in your body.
Selzentry is used with other medications to treat CCR5-tropic HIV type 1, a virus that can cause acquired immunodeficiency syndrome (AIDS). Selzentry is not a cure for HIV or AIDS.
Selzentry is for use in adults and children who weigh at least 4.4 pounds (2 kilograms).
Selzentry side effects
Get emergency medical help if you have signs of an allergic reaction to Selzentry (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).
Stop taking Selzentry and seek medical treatment at once if you have a serious drug reaction that can affect many parts of your body (especially your liver). Symptoms may include: itching or rash, fever, swollen glands, muscle or joint aches, severe weakness, unusual bruising, upper stomach pain, vomiting, dark urine, or jaundice (yellowing of the skin or eyes).
Call your doctor at once if you have a side effect such as:
Selzentry affects your immune system, which may cause certain side effects (even weeks or months after you've taken this medicine). Tell your doctor if you have:
Common Selzentry side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Selzentry
If you have severe or end-stage kidney disease, you may not be able to take Selzentry if you use certain medications, including some antibiotics or antifungal medications, some heart or blood pressure medicines, St. John's wort, and certain drugs to treat hepatitis or tuberculosis. Tell your doctor about all other medications you use.
To make sure Selzentry is safe for you, tell your doctor if you have ever had:
Maraviroc affects your immune system and may possibly increase your risk of developing infections or cancer. Ask your doctor about this risk.
Tell your doctor if you are pregnant, and use your medications properly to control your infection. HIV can be passed to your baby if the virus is not controlled during pregnancy. Your name may be listed on a registry to track any effects of antiviral medicine on the baby.
Women with HIV or AIDS should not breastfeed a baby. Even if your baby is born without HIV, the virus may be passed to the baby in your breast milk.
Selzentry is not approved for a premature baby, or a child who weighs less than 4.4 pounds (2 kilograms).
Relate drugs
How to use Selzentry
Usual Adult Dose for HIV Infection:
With potent CYP450 3A inhibitors (with or without a potent CYP450 3A inducer) including protease inhibitors (except tipranavir/ritonavir), delavirdine, elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin, other potent CYP450 3A inhibitors (e.g., nefazodone, telithromycin), Boceprevir: 150 mg orally twice a day With noninteracting concomitant medications, including tipranavir/ritonavir, Nevirapine, raltegravir, all NRTIs, Enfuvirtide: 300 mg orally twice a day With potent CYP450 3A inducers (without a potent CYP450 3A inhibitor) including efavirenz, rifampin, etravirine, Carbamazepine, phenobarbital, phenytoin: 600 mg orally twice a day Comments: -Noninteracting concomitant medications include all agents that are not potent CYP450 3A inhibitors or inducers. Use: In combination with other antiretroviral agents, for the treatment of only C-C chemokine receptor type 5 (CCR5)-tropic HIV-1 infection
Usual Pediatric Dose for HIV Infection:
2 Years or Older: With potent CYP450 3A inhibitors (with or without a potent CYP450 3A inducer) including protease inhibitors (except tipranavir/ritonavir), delavirdine, elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin, other potent CYP450 3A inhibitors (e.g., nefazodone, telithromycin), boceprevir: -Weight 10 to less than 20 kg: 50 mg orally twice a day -Weight 20 to less than 30 kg: ---Oral solution: 80 mg orally twice a day ---Tablets: 75 mg orally twice a day -Weight 30 to less than 40 kg: 100 mg orally twice a day -Weight at least 40 kg: 150 mg orally twice a day With noninteracting concomitant medications, including tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, enfuvirtide: -Weight less than 30 kg: Not recommended. -Weight at least 30 kg: 300 mg orally twice a day With potent CYP450 3A inducers (without a potent CYP450 3A inhibitor) including efavirenz, rifampin, etravirine, carbamazepine, phenobarbital, phenytoin: Not recommended. Comments: -Recommended dose should be based on body weight and should not exceed the recommended adult dose. -Noninteracting concomitant medications include all agents that are not potent CYP450 3A inhibitors or inducers. Use: In combination with other antiretroviral agents, for the treatment of only CCR5-tropic HIV-1 infection
Warnings
If you have severe kidney disease, you may not be able to take Selzentry if you use certain other medications. Tell your doctor about all other medications you use.
Selzentry may cause serious liver problems. Stop taking this medicine and seek medical treatment at once if you have a serious drug reaction that can harm your liver. Symptoms may include: itching or rash, vomiting, upper stomach pain, dark urine, or jaundice (yellowing of the skin or eyes).
What other drugs will affect Selzentry
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Many drugs may interact with maraviroc. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions